Deprescribing Consultations
Peer Consultation on Psychiatric Deprescribing
Deprescribing decisions are some of the most clinically complex a prescriber faces. Knowing whether a taper is warranted, which medication to reduce first, how to pace it, and how to interpret what emerges along the way requires a level of judgment that formal training rarely covers in depth. I’ve spent the better part of my career focused on exactly this, and I’m available to consult with colleagues at any stage of the process.
This service is for psychiatrists, psychiatric nurse practitioners, primary care providers, and other licensed prescribers managing complex psychotropic regimens who want a second expert perspective.
What a Consultation Covers
A consultation can address wherever you are in the process. That might mean working through the rationale for initiating a taper, thinking through sequencing in a polypharmacy case, troubleshooting a taper that’s hit a wall, or distinguishing withdrawal symptoms from relapse. Cross-tapering, transition to monotherapy, and managing patient reluctance are also common topics.
My approach is collaborative and specific. I’ll review the case thoroughly and provide clear, evidence-informed guidance that accounts for the clinical picture in front of you, not a generalized protocol.
Consultation Fees
| Consultation Type | Duration | Fee |
|---|---|---|
| Initial Consultation | 60 minutes | $500 |
| Follow-Up (same case) | 45 minutes | $300 |
My Credentials in Deprescribing
I authored the first book on psychiatric deprescribing, published by Oxford University Press. I have more than 15 highly cited papers on deprescribing, marijuana, and psychosis.
I served as a research clinician on multiple investigational drug trials at Mount Sinai, taught psychopharmacology at both Yale and Mount Sinai, and led the outpatient psychiatric service at Mount Sinai for five years.
Relevant published research:
-
Deprescribing antipsychotics: a guide for clinicians (BJPsych Advances)
-
Collaborative deprescribing in borderline conditions (HRP Journal)
-
Published work in Psychiatric Services, The Lancet Psychiatry, and Therapeutic Advances in Psychopharmacology